Pre-treatment prediction of response to pegylated-interferon plus ribavarin for chronic hepatitis C using RVR

Journal of Hepatology

Volumn 55, Issue 5, 2011, Pages 1162-1164

  Jafferbhoy, H ^a   Miller, M H ^a   El Wahed, Z ^a   Dillon, J F ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28; LIPID; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN;

DNA POLYMORPHISM; DRUG ABUSE; DRUG SENSITIVITY; FATTY LIVER; HEALTH CARE COST; HEPATITIS C; HUMAN; LETTER; LIVER CIRRHOSIS; MEDICAL DECISION MAKING; PATIENT CARE; PREMEDICATION; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; VENOUS PRESSURE; VIRUS LOAD; VIRUS RESISTANCE;

FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I; INTERLEUKINS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBAVIRIN;

EID: 80054734910     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.04.005     Document Type: Letter

References (2)

1. M. Kurosaki, Y. Tanaka, N. Nishida, N. Sakamoto, N. Enomoto, and M. Honda Pre-treatment prediction of response to pegylated-interferon plus ribavarin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors J Hepatol 54 2011 439 448
2. Y. Jian-Wu, W. Gui-Qiang, S. Li-Jie, L. Xiao-Guang, and L. Shu-Chen Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon a-2a and ribavirin J Gastroenterol Hepatol 22 2007 832 836